A magnetic resonance imaging (MRI) scan is a medical camera that uses strong magnets and radio waves to create detailed pictures of the body’s organs and tissues without surgery or X-rays. Investors care because MRI machines and the services around them represent significant capital spending, recurring revenue from scans, and influence on clinical trials, hospital budgets, and healthcare reimbursements—factors that affect the financial outlook of medical device makers and providers.
magnetic resonance spectroscopic imaging (mrsi)medical
Magnetic resonance spectroscopic imaging (MRSI) is an advanced scanning method that combines MRI’s anatomical pictures with a map of the chemical makeup of tissues, showing not just structure but what molecules are present and where. Think of it like a satellite image that also labels the ingredients under the surface; for investors, MRSI can affect the value and adoption of medical devices, diagnostics and treatments by improving diagnosis, tracking therapy response, and influencing regulatory approval and clinical trial outcomes.
in vivomedical
In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.
metastasismedical
Metastasis is the process by which cancer cells break away from a primary tumor and travel to other parts of the body, where they form new tumors — like seeds carried by wind taking root in distant soil. It matters to investors because metastatic disease often requires more complex, longer-term treatments, drives larger market demand for advanced therapies, and strongly influences clinical trial design, regulatory decisions, and a drug’s commercial value.
brain plasticitymedical
The brain’s ability to reorganize its structure and function in response to learning, injury, or experience, like a house being remodeled to suit new needs or a software program receiving updates. It matters to investors because therapies, devices, or drugs that enhance or harness this adaptability can drive market growth and valuation by offering new treatments for neurological conditions, improving recovery outcomes, or expanding long-term care and cognitive health markets.
biomarkersmedical
Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
World’s highest-field MRI system provides leading disease biology research capabilities
BILLERICA, Mass.--(BUSINESS WIRE)--
Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world’s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue microstructure, and localized metabolism and dynamics are critical.
Delivery of BioSpec 18 Tesla MRI to Champalimaud
Installed at the Champalimaud Foundation’s preclinical MRI laboratory in Lisbon under the leadership of Professor Noam Shemesh, the BioSpec 18T supports advanced neuroscience and oncology research for in vivo studies of cancer, metastasis, brain plasticity and neural activity in preclinical models, while supporting the discovery of novel imaging biomarkers with translational relevance. The 18 Tesla system complements Champalimaud’s existing 16.4 Tesla (700 MHz) vertical-bore MRI/NMR and 9.4 Tesla horizontal-bore MRI.
“We are very excited to explore the full research potential of this novel and unique 18 Tesla system to advance our understanding of biological mechanisms in healthy and diseased conditions,” said Prof. Noam Shemesh, Principal Investigator at Champalimaud. “We will use its ultra-high field and sensitivity to enable investigations of microstructure and localized metabolic dynamics in the brain and in cancer.”
“Providing leading researchers with ultra-high field MRI is a key part of Bruker’s mission in preclinical imaging,” said Dr. Tim Wokrina, Product Manager MRI at Bruker. “We are very pleased to support the Champalimaud Foundation’s neuroscience and oncology research programs.”
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy, as well as in industrial and cleantech research, and semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, proteomics and multiomics, spatial and single-cell biology, structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
